HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 11, November 2019 – Evaluating cost effectiveness of genomic profiling       » Ion treatment offers new hope for cancer patients       » Empowering sustainability through innovation       » Meeting clinical needs in Asia with HealthTech       » The key in diagnosis and treatment       » Singapore's first private co-working laboratory and office space       » Singapore-based MedTech company announced as winner of 2019 Asia Pacific Showcase Competition at The MedTech Forum      
Vol 23, No. 11, November 2019For e-subscribers (PDF)
INSIDE INDUSTRY
Boston-based Singapore start-up gains FDA approval for AI-powered analytics engine for physiological monitoring
Biofourmis received approval from the U.S. Food and Drug Administration (FDA) for its Biovitals™ Analytics Engine in May 2019.

Digital therapeutics company, Biofourmis, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its machine-learning and artificial intelligence (AI)-powered Biovitals™ Analytics Engine as a medical device for ambulatory physiological monitoring.

This regulatory approval of the Biovitals™ Analytics Engine is part of FDA’s growing recognition of machine-learning and AI in the Software as a Medical Device category.

“This milestone approval is foundational to the Biovitals™ ecosystem, which includes not only our most advanced solution, BiovitalsHF™ for heart failure—but also our range of solutions across therapeutic areas, such as pain, oncology, sleep disorders and others in development,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “Receiving this important regulatory approval will only accelerate the development and commercialization of these innovative digital therapeutic solutions.”

This FDA approval is the second market authorization for Biofourmis, having earned the agency’s approval in May 2019 for its Biovitals™ RhythmAnalytics™ platform, a cloud-based software for automated interpretation of over 15 types of cardiac arrhythmias. The newly cleared Analytics Engine is a much broader approval to process multiple physiology signals, as the technology serves as the foundation for all of Biofourmis’ digital therapeutics product pipeline.

The Biovitals™ Analytics Engine receives physiologic data in near real-time from FDA-cleared sensors and leverages AI and machine learning to identify the correlation between multiple vital signs and the patient’s daily activities. The Biovitals™ Analytics Engine computes a time series Biovitals™ Index, which reflects and alerts providers to changes in patients measured vital signs from their baseline.This advance notice provides ample time for the clinician to take the necessary clinical steps to change the trajectory of the disease.

In addition to benefitting patients, the Biovitals™ platform can potentially reduce hospital readmissions and decreases the need for emergency department (ED) visits.

“As the healthcare industry transitions to risk-bearing, value-based care models, tools such as the Biovitals™ Analytics Engine are essential to efficiently and effectively monitor and detect changes in patients’ health status before an adverse event leads to an ED visit or a hospital readmission,” said Maulik Majmudar, MD, a cardiologist and Biofourmis Clinical Advisory Board member.

Click here for the complete issue.

NEWS CRUNCH  
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
news The Proteona Oncology Challenge using ESCAPETM Single Cell Proteogenomic Analysis
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
November:
Evaluating cost effectiveness of genomic profiling
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy